- Home
- GNLN vs BIAF Comparison
GNLN vs BIAF Comparison
Compare GNLN & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNLN
- BIAF
- Stock Information
- Founded
- GNLN 2005
- BIAF 2014
- Country
- GNLN United States
- BIAF United States
- Employees
- GNLN N/A
- BIAF N/A
- Industry
- GNLN Durable Goods
- BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- GNLN Consumer Discretionary
- BIAF Health Care
- Exchange
- GNLN Nasdaq
- BIAF Nasdaq
- Market Cap
- GNLN 12.9M
- BIAF 12.2M
- IPO Year
- GNLN 2019
- BIAF 2022
- Fundamental
- Price
- GNLN $0.01
- BIAF $0.30
- Analyst Decision
- GNLN
- BIAF Hold
- Analyst Count
- GNLN 0
- BIAF 1
- Target Price
- GNLN N/A
- BIAF N/A
- AVG Volume (30 Days)
- GNLN 534.9M
- BIAF 11.2M
- Earning Date
- GNLN 08-13-2025
- BIAF 08-13-2025
- Dividend Yield
- GNLN N/A
- BIAF N/A
- EPS Growth
- GNLN N/A
- BIAF N/A
- EPS
- GNLN N/A
- BIAF N/A
- Revenue
- GNLN $9,818,000.00
- BIAF $8,809,228.00
- Revenue This Year
- GNLN $1,541.21
- BIAF N/A
- Revenue Next Year
- GNLN N/A
- BIAF $20.00
- P/E Ratio
- GNLN N/A
- BIAF N/A
- Revenue Growth
- GNLN N/A
- BIAF 78.40
- 52 Week Low
- GNLN $0.01
- BIAF $0.16
- 52 Week High
- GNLN $21.80
- BIAF $2.99
- Technical
- Relative Strength Index (RSI)
- GNLN 28.32
- BIAF 50.96
- Support Level
- GNLN $0.01
- BIAF $0.22
- Resistance Level
- GNLN $0.02
- BIAF $0.46
- Average True Range (ATR)
- GNLN 0.00
- BIAF 0.04
- MACD
- GNLN 0.00
- BIAF 0.01
- Stochastic Oscillator
- GNLN 9.09
- BIAF 30.51
About GNLN Greenlane Holdings Inc.
Greenlane Holdings Inc is a platform for the development and distribution of premium cannabis accessories, vape devices, and lifestyle products. It provides a wide array of consumer ancillary products and industrial ancillary products to thousands of cannabis producers, processors, brands, and retailers (Cannabis Operators). In addition, it serves specialty retailers, smoke shops, head shops, convenience stores, and consumers directly through its proprietary web stores and large online marketplaces such as Amazon. Its geographical segment includes the United States, Canada, and Europe. It derives a majority of revenue from the United States.
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.